CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 152 enrolled
Drug / intervention
Nasal and Bronchial Samplingother
Likely dose
Not stated in record
Key inclusion· 5
  • ✓Infants aged 2 weeks to 24 months
  • ✓Presentation to Emergency Department with upper respiratory tract infection during RSV season (October–March), OR documented RSV infection admitted to paediatric wards
  • ✓For Group 3 (PICU): documented RSV infection by rapid test and/or PCR, weight >2 kg, conventional ventilator with endotracheal tube >3.0 mm diameter
  • ✓Control Group 1: healthy infants aged 2 weeks–24 months attending routine outpatient appointments or elective surgery
Key exclusion· 12
  • ✕Any local or systemic factor influencing safety of nasal sampling
  • ✕Bilateral indwelling nasal catheters or local nasal pathology preventing access for nasal sampling
  • ✕Bleeding disorders or risk of bleeding
  • ✕Concurrent enrollment in another interventional study

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03062917
NCT03062917N/ACompleted
CompareCT.gov

Validation of Nasal and Bronchial Absorption Sampling Methods for the Assessment of RSV Bronchiolitis in Babies and Children

Imperial College Healthcare NHS Trust·interventional·Posted Feb 24, 2017·Updated Nov 12, 2019

In Brief

A clinical study evaluating Nasal and Bronchial Sampling for Bronchiolitis and 3 related conditions. Completed, enrolled 152 participants across 1 site.

Detailed Summary

This study will compare the novel methods of NS and BS with the standard technique of nasophayngeal aspiration (NPA) and routine ETT suction. We shall assess the samples for diagnosis of RSV, viral load and immune responses in the airways of babies with RSV infection. We shall also assess the genetics of babies included in this study, to see if they may be vulnerable to RSV infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBronchiolitis, Bronchiolitis, Viral, RSV Infection, Respiratory Failure
CountriesUnited Kingdom
CollaboratorsPulmocide Ltd

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 24, 2017
Enrollment StartOct 2, 2015
Primary CompletionJun 30, 2018
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.4 years ago

Interventions

Nasal and Bronchial Samplingother

Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.